Facebook
Twitter
LinkedIn
ForwardNCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens. The use of these new therapies is complex because some patients may have contraindications to therapy or may have unusual adverse reactions to these therapies, which are unique to the individual regimens. Patients with adverse events may be able to continue treatment with the combination immunotherapy + chemotherapy regimens if the adverse events are identified quickly and if they receive appropriate management including supportive care. New targeted therapies are now recommended for patients with metastatic NSCLC. It is difficult for case managers and other health care providers to remain up-to-date about the nuances of treatment with immunotherapy regimens and newer targeted therapy regimens so they can ensure that patients are receiving the most appropriate treatment.
Target Audience
This activity is designed to meet the educational needs of case managers, medical directors, physicians, nurses, pharmacists, and other health care professionals who manage the care of patients with cancer. These webinars may be of particular interest to those in care coordination roles and those who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions in both managed care organizations and clinical settings.
Learning Objectives
Following this activity, participants should be able to:
- Describe the different recommended immunotherapy regimens for patients with metastatic non-small cell lung cancer (NSCLC), including how to sequence therapy to manage these patients.
- Recognize the adverse events that may occur in patients receiving immunotherapy regimens or targeted therapy for metastatic NSCLC.
- Review the different recommended targeted therapy options for patients with metastatic NSCLC with specific genetic alterations including how to sequence therapy to optimize the management of these patients.
Leora Horn, MD, MSc
Vanderbilt-Ingram Cancer Center
Emily A. Skotte, MSN, APRN, ACNP
Vanderbilt-Ingram Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses no relevant financial relationships:
Emily A. Skotte, MSN, APRN, ACNP
The faculty listed below discloses the following relevant financial relationships:
Leora Horn, MD, MSc
AstraZeneca Pharmaceuticals LP: Consulting Fee
Boehringer Ingelheim GmbH: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
EMD Serono: Consulting Fee
Genentech, Inc.: Consulting Fee
Incyte Corporation: Consulting Fee
Merck & Co., Inc.: Consulting Fee
XCOVERY: Consulting Fee; Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Heather Matt; Melanie Moletzsky; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Miranda Hughes, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hour (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-19-078-L01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.25 CE contact hour. Activity Code: I00040060; Approval #: 190004582
Available Credit
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 CCM clock hours
- 1.25 Participation
Price
This webinar was presented live one time only on Thursday, December 19, 2019, from 12:00 - 1:15 PM Eastern Standard Time (EST) (UTC -5).
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing